What is driving the intraday drop in CURN.SW stock today?

The intraday drop to CHF24.20 is driven by trial uncertainty and valuation concerns. Curatis is a small-cap biotech with negative EPS and limited liquidity, so clinical or financing headlines tend to amplify intraday moves in CURN.SW stock.

What is Meyka AI’s view and grade for CURN.SW stock?

Meyka AI rates CURN.SW with a score out of 100 at 63.33, graded B with a HOLD suggestion. The grade reflects benchmark, sector, metrics, forecasts and analyst sentiment and is informational, not investment advice.

Does Meyka AI provide a price forecast for CURN.SW stock?

Yes. Meyka AI's forecast model projects a monthly level of CHF18.59 for CURN.SW stock, implying roughly a -23.18% downside from CHF24.20. Forecasts are model-based and not guarantees.

Which catalysts should investors watch for CURN.SW stock?

Investors should watch Phase II readouts for C-PTBE-01 and C-AM-01, licensing deals, and any cash-raising announcements. Those events typically drive price moves for development-stage biotechs like CURN.SW stock.

CH Stocks

CURN.SW stock falls 6.92% to CHF24.20 intraday 13 Mar 2026: watch clinical catalysts

ByDanny Kontos March 13, 2026March 13, 2026

CURN.SW stock opened at CHF23.40 and is trading at CHF24.20 on the SIX exchange intraday on 13 Mar 2026, down 6.92% from the previous close of CHF26.00. Volume is light at 1,871 shares versus an average of 4,804, but relative volume is elevated at 2.34x, signaling outsized intraday moves. The Healthcare sector is down 1.16% today, but Curatis Holding AG is underperforming peers as traders react to valuation and trial-risk concerns. We break down the drivers, financials, technicals, and Meyka AI’s forecast for near-term price action.